Saturday, 13 September, 2025г.
russian english deutsch french spanish portuguese czech greek georgian chinese japanese korean indonesian turkish thai uzbek

пример: покупка автомобиля в Запорожье

 

Dr. Heinemann on Implications of SIRFLOX Study for mCRC

Dr. Heinemann on Implications of SIRFLOX Study for mCRCУ вашего броузера проблема в совместимости с HTML5
Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the broad clinical implications of the SIRFLOX findings for patients with metastatic colorectal cancer (mCRC).
Опубликовано: 07-10-2016
Теги: cancer oncology

Похожие видео
Dr. Heinemann on Using Depth of Response in Pretreated Patients With CRC

Dr. Heinemann on Using Depth of Response in Pretreated Patients With CRC00:59

Volker Heinemann, University of Munich, Munich, Germany

Volker Heinemann, University of Munich, Munich, Germany06:14

ASCO 2008: Cetuximab for metastatic colorectal cancer (mCRC)

ASCO 2008: Cetuximab for metastatic colorectal cancer (mCRC)06:29

Conducting Extended RAS Testing in Colorectal Cancer

Conducting Extended RAS Testing in Colorectal Cancer07:43

Мой аккаунт

Вход / Log In